Study to Determine the Pharmacokinetics of Product 0405

• Status: Withdrawn
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fougera Pharmaceuticals Inc.

Criteria

Inclusion Criteria:

• Clinical diagnosis of Atopic Dermatitis

• Good health with the exception of Atopic Dermatitis

• Percent body surface area minimums

Exclusion Criteria:

• Subject who are nursing, pregnant or planning a pregnancy